Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label dose-escalation study to assess the safety and bioavailability of single oral doses of azacitidine in patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), or solid tumors

Next Previous
Trial Profile

An open-label dose-escalation study to assess the safety and bioavailability of single oral doses of azacitidine in patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), or solid tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2007

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pharmion Corporation

Most Recent Events

  • 23 Apr 2007 Status change from in recruiting to completed.
  • 15 Feb 2007 Status changed from planning to recruiting.
  • 02 Feb 2007 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top